BofA sees limited impact to Eli Lilly's franchise from Novo's GLP-1 price update [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
BofA says that today's announcement that Novo Nordisk ( NVO ) plans to slash GLP-1 list prices offers a flashy headline, but in the firm's view the update is unlikely to have any material impact on the U.S. market. BofA sees today's move as an attempt to reduce copay/coinsurance costs to patients in settings where that figure is calculated of list/WAC price. More broadly, the firm thinks it's fair for investors to wonder if/when commercial reimbursement of GLP-1's could become more commonplace, with BofA channel checks suggesting this may may hinge on convergence of PBM price and consumer cash price. Taken in aggregate, the firm sees limited impact to Eli Lilly's ( LLY ) GLP-1 franchise given no clear indication Novo is moving more aggressively on lower net pricing in the commercial insurance channel, greater anticipated contribution from cash pay and U.S. government channels which are unimpacted by today's update. BofA maintains a Buy rating on Eli Lilly. Claim 50% Off TipRanks Pr
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk Shares Sink 21% as Obesity Shot Trails Lilly Rival [Yahoo! Finance]Yahoo! Finance
- SA analyst upgrades/downgrades: NVDA, NKE, SMCI, NVO [Seeking Alpha]Seeking Alpha
- Clinical ink Appoints Dr. Christian Born Djurhuus, MD, PhD as Chief Science OfficerPR Web
- Novo Nordisk's Torrid Week Erases Last of Wegovy-Fueled Gains [Yahoo! Finance]Yahoo! Finance
- 12 Press Releases You Need to See This Week [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 2/23/26 - Form 6-K
- 2/23/26 - Form 6-K
- 2/20/26 - Form 6-K
- NVO's page on the SEC website